Ignite Creation Date:
2024-05-06 @ 4:15 PM
Last Modification Date:
2024-10-26 @ 2:06 PM
Study NCT ID:
NCT04923269
Status:
COMPLETED
Last Update Posted:
2021-12-17
First Post:
2021-06-09
Brief Title:
A Study of LY3532226 in Healthy Participants
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Single-Ascending Dose Study to Evaluate the Safety Tolerability and Pharmacokinetics of LY3532226 in Healthy Participants
Status:
COMPLETED
Status Verified Date:
2021-12-15
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3532226 in healthy participants Blood tests will be performed to check how much LY3532226 gets into the bloodstream and how long it takes the body to eliminate it This study will last approximately 8 weeks including screening period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| J2V-MC-GZLA | OTHER | Eli Lilly and Company | None |